Related Experiment Videos
Treating renal artery stenosis. A statement pro endovascular therapy
Martin Schillinger1, Erich Minar, Ramazanali Ahmadi
1Division of Angiology, Department of Internal Medicine II, Vienna General Hospital, Medical School, Vienna, Austria. martin.schillinger@akh-wien.ac.at
Herz
|February 18, 2004
Summary
Renal artery stenosis (RAS) treatment via angioplasty can improve renal function and reduce blood pressure medication needs. However, careful patient selection is crucial due to potential risks and unclear indications for intervention.
Area of Science:
- Interventional Cardiology
- Nephrology
- Vascular Surgery
Background:
- Renal artery stenosis (RAS) can cause hypertension and ischemic nephropathy.
- Endovascular revascularization is a primary treatment for RAS.
Purpose of the Study:
- To review the beneficial effects of percutaneous transluminal angioplasty (PTA) and stenting in patients with RAS.
- To discuss the ongoing debate regarding indications for interventional treatment of RAS.
Main Methods:
- Review of current literature on endovascular revascularization for RAS.
- Analysis of technical success rates, complication frequencies, and long-term patency.
- Evaluation of outcomes related to hypertension and ischemic nephropathy.
Main Results:
- High technical success rates (>95%) and good long-term patency are achievable with endovascular treatment.
- Angioplasty rarely cures hypertension but can reduce medication requirements.
- Revascularization may stabilize or slow the decline of renal function in ischemic nephropathy.
- Angioplasty carries a risk of inducing renal deterioration.
Conclusions:
- Careful patient selection is paramount for successful renal interventions.
- Current data are insufficient to provide definitive recommendations for interventional treatment of RAS.
- Further research is needed to clarify optimal patient selection criteria for RAS revascularization.